SK Life Science Inc., a subsidiary of South Kore-based SK Biopharmaceuticals Co. Ltd, announced on Thursday that it has received US Food and Drug administration (FDA) approval for the investigational new drug (IND) application to study SKL27969 as a potential treatment for advanced solid tumours.
The company is to carry out a Phase 1/2 open-label, non-randomised, multicentre, dose escalation and expansion study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SKL27969 in adult patients with solid tumours.
Marc Kamin, MD, chief medical officer at SK life science, said, 'We look forward to learning more about the potential of SKL27969 as a treatment option for a range of advanced solid tumours. We are excited to expand our R&D efforts into discovering potential new therapies for cancer.'
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain